medigraphic.com

2008, Número 1

<< Anterior Siguiente >>

Rev Med Hosp Gen Mex 2008; 71 (1)


Prevalencia del síndrome metabólico entre adultos mexicanos no diabéticos, usando las definiciones de la OMS, NCEP-ATPIIIa e IDF

González-Chávez A, Simental L, Elizondo-Argueta S, Sánchez ZJ, Gutiérrez SG, Guerrero-Romero F

Idioma: Español
Referencias bibliográficas: 30
Paginas: 11-19
Archivo PDF: 213.28 Kb.


RESUMEN

Objetivo: Determinar la prevalencia de síndrome metabólico en una población de adultos mexicanos no diabéticos con los criterios de la Federación Internacional de Diabetes (IDF), de la Organización Mundial de la Salud (OMS) y la definición del Programa Nacional de Colesterol-ATP III modificada (NCEP-ATPIIIa). Material y métodos: Estudio transversal en el que se incluyeron 189 individuos aparentemente sanos, hombres y mujeres no embarazadas, mayores de 18 años habitantes de la Ciudad de México. Una historia clínica detallada y una exploración física completa se llevaron a cabo para colectar la información sobre variables antropométricas y de laboratorio. El síndrome metabólico se definió de acuerdo a los criterios de la IDF, OMS y de la NCEP-ATPIIIa. Resultados: Participaron un total de 189 sujetos, el 66% correspondieron al sexo femenino, con edad media de 38.27 ± 12 años en las mujeres y de 39.29 ± 14 años en los hombres. Los hombres tuvieron valores medios significativamente más altos de peso, talla y ácido úrico (p ‹ 0.001) comparados con las mujeres. Por otro lado, las mujeres tuvieron concentraciones séricas más elevadas de C-HDL (p ‹ 0.001). No hubo diferencias significativas en los valores de edad, índice de masa corporal (IMC), índice cintura-cadera (ICC), presión arterial sistólica (PAS), presión arterial diastólica (PAD), glucosa en ayuno, colesterol total y triglicéridos entre hombres y mujeres. Las prevalencias del síndrome metabólico con los diferentes criterios fueron de 46.5, 43.3 y 36.5% para ATP-IIIa, IDF y OMS, respectivamente. Conclusiones: La prevalencia del síndrome metabólico en México, definida por los criterios de la ATP-IIIa e IDF fue mayor que la estimada por la OMS.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Haffner SM. Valdez RA, Hazuda HP, Mitchell BD, Morales PA, Stern MP. Prospective analysis of the insulin-resistance syndrome (syndrome X). Diabetes 1992; 41: 715-722.

  2. Isomaa B, Alegren P, Tuomi T et al, Cardiovascular morbidity and mortality associated with the metabolic syndrome. Diabetes Care 2001; 24: 683-689.

  3. Trevisan M. Liu J, Bahsas FB, Menotti A. Syndrome X and mortality: A population-based study. Am J Epidemiol 1998; 148: 958-966.

  4. Mensah GA. Obesity, Metabolic syndrome and type 2 diabetes: Emerging epidemics and their cardiovascular implications. Cardiol Clin 2004; 22: 485-504.

  5. Haffner SM. Prevalence and characteristic of the metabolic syndrome in the San Antonio Heart and Framingham offspring Studies. Diabetes 2003; 52: 2160-2167.

  6. Grundy SM. Metabolic syndrome: Connecting and reconciling cardiovascular and diabetes worlds. JACC 2006; 47 (6): 1093-1100.

  7. Reaven GM. Banting Lecture 1988. Role of insulin resistance in human disease. Diabetes 1988; 34: 416-422.

  8. Alberti KGM, Zimmet PZ. For the WHO Consultation: Definition, diagnosis and classification of diabetes mellitus and its complications. PART 1: Diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabetes Med 1998; 15: 539-553.

  9. Expert Panel on Detection, Evaluation, and Treatment of High blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001; 285: 2486-2497.

  10. Ford ES. A comparison of the prevalence of the metabolic syndrome using two proposed definitions. Diabetes Care 2003; 26: 575-581.

  11. Alberti KGM, Zimmet P, Shaw J. The metabolic syndrome a new worldwide definition. Lancet 2005; 366: 1059-1062.

  12. Aguilar SCA. High prevalence of the metabolic syndrome in Mexico. Arch Med Res 2004; 35: 76-81.

  13. Aguilar SCA. Analysis of the agreement between the WHO criteria and the National Cholesterol Education Program III. Definition of the metabolic syndrome: Results from population based survey. Diabetes Care 2003; 26: 1635.

  14. Ford ES. Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care 2005; 28; 2745-2749.

  15. Danadian K, Balasekaran G, Lewy V et al. Insulin sentivity in African-American children with and without family history of type 2 diabetes. Diabetes Care 1999; 22: 1325-1329.

  16. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005; 28 (suppl 1): s37-s42.

  17. Warnik GR, Alberts JJ. Heparin-Mn2 + quantitation of high density lipoprotein cholesterol: An ultra filtration procedure for lipemic samples. J Clin Chem Biochem 1978; 24: 900.904.

  18. Friedewald WT, Kevy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use the preparative ultracentrifuge. J Clin Chem Biochem 1972; 18: 499-502.

  19. Arslanian SA, Saad R, Lewy V et al. Hyperinsulinemia in African. American children: Decreased insulin clearance and increased insulin secretion and its relationship to sensitivity. Diabetes 2002; 51: 3014-3019.

  20. Matthews DR,Hosker JP,Rudenski AS et al. Homeostasis model assessment: Insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetología 1985; 28: 412-419.

  21. Guerrero-Romero F. Rodriguez M. Concordance between the 2005 International Diabetes Federation definition for diagnosing metabolic syndrome with the National Cholesterol Education Program Adult Treatment Panel III and the World Health Organization definitions. Diabetes Care 2005; 28: 2588-2589.

  22. Serrano LC – Ríos M, Martinez-Larrad MT. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program–Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006; 29: 685-691.

  23. Lee J, Ma S, Heng D. Should central obesity be an optional risk factor of the metabolic syndrome? Ischemic heart disease risk the Singapore cardiovascular cohort study. Diabetes Care 2007; 30: 343-347.

  24. Rojas R, Palma O, Quintana I. Adultos. En: Olaiz G, Rivera J, Shamah T, Rojas R, Villalpando S, Hernández M, Sepúlveda J (eds). Encuesta Nacional de Salud y Nutrición 2006 (ENSANUT 2006 ). México, DF: Instituto Nacional de Salud Pública, 2006. pp 75–82.

  25. Serrano LC, Rios M, Martinez-Larrad MT. Geographic variations of the International Diabetes Federation and the National Cholesterol Education Program–Adult Treatment Panel III definitions of the metabolic syndrome in nondiabetic subjects. Diabetes Care 2006; 29: 685-691.

  26. Alonso AL, Munguia-Miranda C, Ramos-Ponce D. Waist perimeter cutoff points and prediction of metabolic syndrome risk. A study in a Mexican population. Arch Med Res 2008; 39: 346-351.

  27. Park YW, Zhu S, Palaniappan L, Heshka S et al. The metabolic syndrome: Prevalence and associated risk factor findings in the US population from the Third National Health and Nutrition Examination Survey. 1988-1994. Arch Intern Med 2003; 163: 427-436.

  28. Ilanne-Parikka P, Eriksson JG, Lindstrom J et al. Prevalence of the metabolic syndrome and its components. Diabetes Care 2004; 27: 2135–2140.

  29. Scuteri A, Najjar SS, Morrell CH. The metabolic syndrome in older individuals: Prevalence and prediction of cardiovascular events. Diabetes Care 2005; 28: 882–887.

  30. Ford ES. Increasing prevalence of the metabolic syndrome among U.S. adults. Diabetes Care 2004; 27: 2444-2449.




2020     |     www.medigraphic.com